Length of postoperative ICU stay · Children having heart surgery with cardiopulmonary bypass
1 finding from 1 review
Length of postoperative hospital stay · Children having heart surgery with cardiopulmonary bypass
1 finding from 1 review
Mortality within the longest · Children having heart surgery with cardiopulmonary bypass
Glucocorticoid showed no clear difference in all‐cause mortality at longest compared with placebo (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · Children having heart surgery with cardiopulmonary bypass
Glucocorticoid showed no clear difference in cardiovascular mortality at longest compared with placebo (moderate certainty).
1 finding from 1 review
Failure to separate from CPB · Children having heart surgery with cardiopulmonary bypass
Glucocorticoid showed no clear difference in failure to separate from CPB compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes all‐cause mortality: up to 3 months' (very low certainty).
1 finding from 1 review
Intervention not reported
Health‐related quality of life: up to 3 months ( · participants with alcoholic hepatitis at high risk of mortality and morbidity
The intervention showed no clear difference in health‐related quality of life: up to 3 months ( (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events during treatment · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes serious adverse events during treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Liver‐related mortality: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes liver‐related mortality: up to 3 months' (very low certainty).
1 finding from 1 review
Intervention not reported
Participants with any complication: up to 3 months following randomisation · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes participants with any complication: up to 3 months following… (very low certainty).
1 finding from 1 review
Intervention not reported
Participants with non‐serious adverse events: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes participants with non‐serious adverse events: up to 3 months' (very low certainty).
1 finding from 1 review
All‐cause mortality · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in all‐cause mortality compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in all‐cause non‐fatal serious adverse events compared with same‐dose ICS (high certainty).
1 finding from 1 review
Asthma‐related mortality · adults, chronic asthma: all‐cause mortality
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
All‐cause mortality · children and adolescents with chronic asthma
1 finding from 1 review
Non‐fatal serious adverse events · children and adolescents with chronic asthma
Regular formoterol and ICS showed no clear difference in all‐cause non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
Asthma‐related mortality · children and adolescents with chronic asthma
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · children and adolescents with chronic asthma
It is very uncertain whether regular formoterol and ICS changes asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (very low certainty).
1 finding from 1 review
Linear growth velocity (cm/year) · children up to 18 years of age with persistent asthma
Effects of different delivery devices on growth in children with… showed no clear difference in linear growth velocity (cm/year) compared with chlorofluorocarbon‐metered dose inhaler beclomethasone (low certainty).
1 finding from 1 review